Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG

Cancer

Volumn 112, Issue 11, 2008, Pages 2447-2455

  Kayani, Irfan ^a   Bomanji, Jamshed B ^a   Groves, Ashley ^a   Conway, Gerard ^b   Gacinovic, Sveto ^a   Win, Thida ^c   Dickson, John ^a   Caplin, Martyn ^d   Ell, Peter Joseph ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c LISTER HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Endocrine system; Neuroendocrine tumors; PET CT; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; KI 67 ANTIGEN; TRACER; 68GA DOTATATE; 68GA-DOTATATE; DIAGNOSTIC AGENT; GALLIUM; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION FUNCTION; DIAGNOSTIC IMAGING; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INFORMED CONSENT; MALE; MITOSIS INDEX; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; COMPARATIVE STUDY; MIDDLE AGED; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GALLIUM; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 49049096760     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23469     Document Type: Article

References (23)

1. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumor. Lancet. 1998;352:799-805.
2. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1):172S-8S.
3. 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478-485.
4. Froidevaux S, Eberle AN, Christe M, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer. 2002;98:930-937.
5. 68Ga DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757.
6. Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-DPhe1-Tyr3- octreotide in comparison to [111In]-DTPAOC SPECT: first results in patients with neuroendocine tumors. Mol Imaging Biol. 2003;5:42-48.
7. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
8. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med. 1998;25:79-83.
9. Belhocine T, Foidart J, Rigo P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumors: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727-734.
10. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Metabolic (PET) and receptor (SPET) imaging of well-and less well-differentiated tumors: comparison with the expression of the ki-67 antigen. Nucl Med Commun. 1998;19:641-647.
11. Pasquali C, Rubello D, Sperti C, et al. NET tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 1998;22:588-592.
12. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors:a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
13. Rindi G, Kloppel G., Couvelard A., et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762.
14. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumors. Eur J Nucl Med. 2001;28:478-482.
15. Quigley AM, Buscombe JR, Shah T, et al. Intertumoral variability in functional imaging within patients suffering from NET tumors. An observational, cross-sectional study. Neuroendocrinology. 2005;82:215-220.
16. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumors scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460-466.
17. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115-1122.
18. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
19. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumors with radiolabelelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683-699.
20. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl):13S-7S.
21. Kaltsas GA, Besser GM, Grossmann AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511.
22. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroenodocrine tumors: molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
23. Krenning EP, Valkema R, Kwekkeboom DJ, et al. Molecular imaging as in vivo molecular pathology for gastroenterohepatic neuroendocrine tumors: implications for follow up after therapy. J Nucl Med. 2005;46(suppl 1):76S-82S.